Recent advances in PET probes for hepatocellular carcinoma characterization

References

• Ghouri YA, Mian I, Rowe JH. Review of hepatocellular carcinoma: epidemiology, etiology, and carcinogenesis. J Carcinog. 2017;16:1.
   PubMedGoogle Scholar
• Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340:745–750.
   PubMed Web of Science ®Google Scholar
• Njei B, Rotman Y, Ditah I, et al. Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology. 2015;61:191–199.
   PubMed Web of Science ®Google Scholar
• Petrick JL, Braunlin M, Laversanne M, et al. A International trends in liver cancer incidence, overall and by histologic subtype, 1978–2007. Int J Cancer. 2016;139:1534–1545.
   PubMed Web of Science ®Google Scholar
• Bréchot C. Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology. 2004;127:S56–61.
   PubMed Web of Science ®Google Scholar
• Bandiera S, Billie BC, Hoshida Y, et al. Chronic hepatitis C virus infection and pathogenesis of hepatocellular carcinoma. Curr Opin Virol. 2016;20:99–105.
   PubMed Web of Science ®Google Scholar
• Bhosale P, Szklaruk J, Silverman PM. Current staging of hepatocellular carcinoma: imaging implications. Cancer Imaging. 2006;6:83–94.
   PubMedGoogle Scholar
• Larcos G, Sorokopud H, Berry G, et al. Sonographic screening for hepatocellular carcinoma in patients with chronic hepatitis or cirrhosis: an evaluation. AJR Am J Roentgenol. 1998;171:433–435.
   PubMed Web of Science ®Google Scholar
• Pateron D, Ganne N, Trinchet JC, et al. Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J Hepatol. 1994;20:65–71.
   PubMed Web of Science ®Google Scholar
• França AV, Elias Junior J, Lima BL, et al. Diagnosis, staging and treatment of hepatocellular carcinoma. Braz J Med Biol Res. 2004;37:1689–1705.
   PubMed Web of Science ®Google Scholar
• Pompili M, Riccardi L, Semeraro S, et al. Contrast-enhanced ultrasound assessment of arterial vascularization of small nodules arising in the cirrhotic liver. Dig Liver Dis. 2008;40:206–215.
   PubMedGoogle Scholar
• Roberts LR, Sirlin CB, Zaiem F, et al. Imaging for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Hepatology. 2018;67:401–421.
   PubMed Web of Science ®Google Scholar
• Stevens WR, Johnson CD, Stephens DH, et al. CT findings in hepatocellular carcinoma: correlation of tumour characteristics with causative factors, tumour size, and histologic tumour grade. Radiology. 1994;191:531–537.
   PubMed Web of Science ®Google Scholar
• Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects. Radiology. 2014;272:635–654.
   PubMed Web of Science ®Google Scholar
• Taouli B, Losada M, Holland A, et al. Magnetic resonance imaging of hepatocellular carcinoma. Gastroenterology. 2004;127(S1):S144–52.
   PubMed Web of Science ®Google Scholar
• Becker-Weidman DJ, Kalb B, Sharma P, et al. Hepatocellular carcinoma lesion characterization: single-institution clinical performance review of multiphase gadolinium-enhanced MR imaging–comparison to prior same-center results after MR systems improvements. Radiology. 2011;261:824–833.
   PubMed Web of Science ®Google Scholar
• Arif-Tiwari H, Kalb B, Chundru S, et al. MRI of hepatocellular carcinoma: an update of current practices. Diagn Interv Radiol. 2014;20:209–221.
   PubMed Web of Science ®Google Scholar
• Renzulli M, Biselli M, Brocchi S, et al. New hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis: a new diagnostic algorithm. Gut. 2018;67:1674–1682.
   PubMed Web of Science ®Google Scholar
• Patella F, Pesapane F, Fumarola EM, et al. CT-MRI LI-RADS v2017: a comprehensive guide for beginners. J Clin Transl Hepatol. 2018;6:222–236.
   PubMed Web of Science ®Google Scholar
• Sirlin C. Use of the liver imaging reporting and data system in hepatocellular carcinoma. Gastroenterol Hepatol. 2017;13:363–365.
   Google Scholar
• Asman Y, Evenson AR, Even-Sapir E, et al. [18F]fludeoxyglucose positron emission tomography and computed tomography as a prognostic tool before liver transplantation, resection, and loco-ablative therapies for hepatocellular carcinoma. Liver Transpl. 2015;21:572–580.
   PubMed Web of Science ®Google Scholar
• Wudel LJ Jr, Delbeke D, Morris D, et al. The role of [18F]fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma. Am Surg. 2003;69:117–126.
   PubMed Web of Science ®Google Scholar
• Izuishi K, Yamamoto Y, Mori H, et al. Molecular mechanisms of [18F]fluorodeoxyglucose accumulation in liver cancer. Oncol Rep. 2014;31:701–706.
   PubMed Web of Science ®Google Scholar
• Delbeke D, Martin WH, Sandler MP, et al. Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch Surg. 1998;133:510–515.
   PubMed Web of Science ®Google Scholar
• Jeng LB, Changlai SP, Shen YY, et al. Limited value of 18F-2-deoxyglucose positron emission tomography to detect hepatocellular carcinoma in hepatitis B virus carriers. Hepatogastroenterology. 2003;50:2154–2156.
   PubMedGoogle Scholar
• Lin CY, Chen JH, Liang JA, et al. 18F-FDG PET or PET/CT for detecting extrahepatic metastases or recurrent hepatocellular carcinoma: a systematic review and meta-analysis. Eur J Radiol. 2012;81:2417–2422.
   PubMed Web of Science ®Google Scholar
• Cho E, Jun CH, Kim BS, et al. 18F-FDG PET CT as a prognostic factor in hepatocellular carcinoma. Turk J Gastroenterol. 2015;26:344–350.
   PubMed Web of Science ®Google Scholar
• Na SJ, Oh JK, Hyun SH, et al. 18F-FDG PET/CT can predict survival of advanced hepatocellular carcinoma patients: a multicenter retrospective cohort study. J Nucl Med. 2017;58:730–736.
   PubMed Web of Science ®Google Scholar
• Jo IY, Son SH, Kim M, et al. Prognostic value of pretreatment (18)F-FDG PET-CT in radiotherapy for patients with hepatocellular carcinoma. Radiat Oncol J. 2015;33:179–187.
   PubMed Web of Science ®Google Scholar
• Lee JW, Hwang SH, Kim DY, et al. Prognostic value of FDG uptake of portal vein tumour thrombosis in patients with locally advanced hepatocellular carcinoma. Clin Nucl Med. 2017;42:e35–e40.
   PubMed Web of Science ®Google Scholar
• Lee JD, Yun M, Lee JM, et al. Analysis of gene expression profiles of hepatocellular carcinomas with regard to 18F-fluorodeoxyglucose uptake pattern on positron emission tomography. Eur J Nucl Med Mol Imaging. 2004;31:1621–1630.
   PubMed Web of Science ®Google Scholar
• Ma W, Jia J, Wang S, et al. The prognostic value of 18F-FDG PET/CT for hepatocellular carcinoma treated with transarterial chemoembolization (TACE). Theranostics. 2014;4:736–744.
   PubMed Web of Science ®Google Scholar
• Benz MR, Allen-Auerbach MS, Eilber FC, et al. Combined assessment of metabolic and volumetric changes for assessment of tumour response in patients with soft-tissue sarcomas. J Nucl Med. 2008;49:1579–1584.
   PubMed Web of Science ®Google Scholar
• Filippi L, Di Costanzo GG, D‘Agostini A, et al. Decrease in total lesion glycolysis and survival after yttrium-90-radioembolization in poorly differentiated hepatocellular carcinoma with portal vein tumour thrombosis. Nucl Med Commun. 2018;39:845–852.
   PubMed Web of Science ®Google Scholar
• Karanikas G, Beheshti M. 11C-acetate PET/CT imaging: physiologic uptake, variants, and pitfalls. PET Clin. 2014 Jul;9(3):339–344. .
   PubMedGoogle Scholar
• Grassi I, Nanni C, Allegri V, et al. The clinical use of PET with (11)C-acetate. Am J Nucl Med Mol Imaging. 2011;2(1):33–47.
   PubMedGoogle Scholar
• Ho CL, Yu SC, Yeung DW. 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med. 2003 Feb;44(2):213–221.
   PubMed Web of Science ®Google Scholar
• Lhommel R, Annet L, Bol A, et al. PET scan with 11C-acetate for the imaging of liver masses: report of a false positive case. Eur J Nucl Med Mol Imaging. 2005;32:629.
   PubMed Web of Science ®Google Scholar
• Park JW, Kim JH, Kim SK, et al. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. J Nucl Med. 2008;49:1912–1921.
   PubMed Web of Science ®Google Scholar
• Huo L, Wu Z, Zhuang H, et al. Dual time point C-11 acetate PET imaging can potentially distinguish focal nodular hyperplasia from primary hepatocellular carcinoma. Clin Nucl Med. 2009 Dec;34(12):874–877.
   PubMed Web of Science ®Google Scholar
• Huo L, Dang Y, Lv J, et al. Application of dual phase imaging of 11C-acetate positron emission tomography on differential diagnosis of small hepatic lesions. PLoS One. 2014;9:e96517.
   PubMed Web of Science ®Google Scholar
• Cheung TT, Ho CL, Lo CM, et al. 11C-acetate and 18F-FDG PET/CT for clinical staging and selection of patients with hepatocellular carcinoma for liver transplantation on the basis of Milan criteria: surgeon‘s perspective. J Nucl Med. 2013;54:192–200.
   PubMed Web of Science ®Google Scholar
• Liu AP, Wong KN, See QW, et al. 11C-acetate positron emission tomography for detection of occult metastatic recurrence in hepatoblastoma. J Pediatr Hematol Oncol. 2016 May;38(4):317–320.
   PubMed Web of Science ®Google Scholar
• Li S, Peck-Radosavljevic M, Ubl P, et al. The value of [11C]-acetate PET and [18F]-FDG PET in hepatocellular carcinoma before and after treatment with transarterial chemoembolization and bevacizumab. Eur J Nucl Med Mol Imaging. 2017;44:1732–1741.
   PubMed Web of Science ®Google Scholar
• Filippi L, Schillaci O, Bagni O. 90Y-radioembolization of hepatocellular carcinoma from a theranostic perspective: towards a personalized approach. Eur J Nucl Med Mol Imaging. 2018;45:2238–2239.
   PubMed Web of Science ®Google Scholar
• Ho CL, Chen S, Cheung SK, et al. Radioembolization with 90Y glass microspheres for hepatocellular carcinoma: significance of pretreatment 11C-acetate and 18F-FDG PET/CT and posttreatment 90Y PET/CT in individualized dose prescription. Eur J Nucl Med Mol Imaging. 2018;45:2110–2121.
   PubMed Web of Science ®Google Scholar
• Cl H, Cheung MK, Chen S, et al. [18F]fluoroacetate positron emission tomography for hepatocellular carcinoma and metastases: an alternative tracer for [11C]acetate? Mol Imaging. 2012;11:229–239.
   PubMed Web of Science ®Google Scholar
• Katz-Brull R, Degani H. Kinetics of choline transport and phosphorylation in human breast cancer cells; NMR application of the zero trans method. Anticancer Res. 1996;16:1375–1380.
   PubMed Web of Science ®Google Scholar
• Zeisel SH. Choline phospholipids: signal transduction and carcinogenesis. Faseb J. 1993;7:551–557.
   PubMed Web of Science ®Google Scholar
• Kuang Y, Salem N, Corn DJ, et al. Transport and metabolism of radiolabeled choline in hepatocellular carcinoma. Mol Pharm. 2010;7:2077–2092.
   PubMed Web of Science ®Google Scholar
• Vali R, Loidl W, Pirich C, et al. Imaging of prostate cancer with PET/CT using (18)F-Fluorocholine. Am J Nucl Med Mol Imaging. 2015;5:96–108.
   PubMed Web of Science ®Google Scholar
• Mertens K, Slaets D, Lambert B, et al. PET with (18)F-labelled choline-based tracers for tumour imaging: a review of the literature. Eur J Nucl Med Mol Imaging. 2010;37:2188–2193.
   PubMed Web of Science ®Google Scholar
• Bagni O, Filippi L, Schillaci O. Incidental detection of colorectal cancer via (18)F-choline PET/CT in a patient with recurrent prostate cancer: usefulness of early images. Clin Nucl Med. 2015;40:e328–330.
   PubMed Web of Science ®Google Scholar
• Salem N, Kuang Y, Wang F, et al. PET imaging of hepatocellular carcinoma with 2-deoxy-2[18F] fluoro-d-glucose, 6-deoxy-6[18F] fluoro-d-glucose, [1−11C]-acetate and [N-methyl-11C]-choline. Q J Nucl Med Mol Imaging. 2009;53:144–156.
   PubMed Web of Science ®Google Scholar
• Kolthammer JA, Corn DJ, Tenley N, et al. PET imaging of hepatocellular carcinoma with 18F-fluoroethylcholine and 11C-choline. Eur J Nucl Med Mol Imaging. 2011;38:1248–1256.
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Nishiyama Y, Kameyama R, et al. Detection of hepatocellular carcinoma using 11C-choline PET: comparison with 18F-FDG PET. J Nucl Med. 2008;49:1245–1248.
   PubMed Web of Science ®Google Scholar
• Wu HB, Wang QS, Li BY, et al. 18F-FDG in conjunction with 11C-choline PET/CT in the diagnosis of hepatocellular carcinoma. Clin Nucl Med. 2011;36:1092–1097.
   PubMed Web of Science ®Google Scholar
• Talbot JN, Gutman F, Fartoux L, et al. PET/CT in patients with hepatocellular carcinoma using [18F] fluorocholine: preliminary comparison with [18F] FDG PET/CT. Eur J Nucl Med Mol Imaging. 2006;33:1285–1289.
   PubMed Web of Science ®Google Scholar
• Talbot JN, Fartoux L, Balogova S, et al. Detection of hepatocellular carcinoma with PET/CT: a prospective comparison of 18F-fluorocholine and 18F-FDG in patients with cirrhosis or chronic liver disease. J Nucl Med. 2010;51:1699–1706.
   PubMed Web of Science ®Google Scholar
• Castilla-Lièvre MA, Franco D, Gervais P, et al. Diagnostic value of combining 11C-choline and 18F-FDG PET/CT in hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2016;43:852–859.
   PubMed Web of Science ®Google Scholar
• Chalaye J, Costentin CE, Luciani A, et al. Positron emission tomography/computed tomography with 18F-fluorocholine improve tumour staging and treatment allocation in patients with hepatocellular carcinoma. J Hepatol. 2018;69:336–344.
   PubMed Web of Science ®Google Scholar
• Hartenbach M, Weber S, Albert NL, et al. Evaluating treatment response of radioembolization in intermediate-stage hepatocellular carcinoma patients using 18F-fluoroethylcholine PET/CT. J Nucl Med. 2015;56:1661–1666.
   PubMed Web of Science ®Google Scholar
• Lanza E, Donadon M, Felisaz P, et al. Refining the management of patients with hepatocellular carcinoma integrating 11C-choline PET/CT scan into the multidisciplinary team discussion. Nucl Med Commun. 2017 Oct;38(10):826–836.
   PubMed Web of Science ®Google Scholar
• Liu D, Khong PL, Gao Y, et al. Radiation dosimetry of whole-body dual-tracer 18F-FDG and 11C-acetate PET/CT for hepatocellular carcinoma. J Nucl Med. 2016;57:907–912.
   PubMed Web of Science ®Google Scholar
• Kong E, Chun KA, Cho IH, et al. Quantitative assessment of simultaneous F-18 FDG PET/MRI in patients with various types of hepatic tumours: correlation between glucose metabolism and apparent diffusion coefficient. PLoS One. 2017;12:e0180184.
   PubMed Web of Science ®Google Scholar
• Hectors SJ, Wagner M, Besa C, et al. Multiparametric FDG-PET/MRI of hepatocellular carcinoma: initial experience. Contrast Media Mol Imaging. 2018;2018:5638283.
   PubMed Web of Science ®Google Scholar
• Sasikumar A, Joy A, Pillai MR, et al. 68Ga-PSMA PET/CT imaging in multiple myeloma. Clin J Nucl Med. 2017;42:e126–e127.
   PubMed Web of Science ®Google Scholar
• Kesler M, Levine C, Hershkovitz D, et al. 68Ga-PSMA is a novel PET-CT tracer for imaging of hepatocellular carcinoma: a prospective pilot study. J Nucl Med. 2018. DOI:10.2967/jnumed.118.214833.
   PubMed Web of Science ®Google Scholar
• Ahmadzadehfar H, Essler M. It is time to move forward into the era of theranostics. EJNMMI Res. 2018. DOI:10.1186/s13550-018-0364-x
   PubMed Web of Science ®Google Scholar